Business
Investors in drugmaker Mesoblast sweat on crucial capital raising – Sydney Morning Herald
The stem cell giant says it needs cash from its existing partnerships to ‘continue as a going concern’.
The ability of the group to continue as a going concern and realise its assets and discharge its liabilities in the normal course of business are dependent on cash inflows from successfully completing the private placement, as well as from existing strategic and financing partnerships, the auditors report said.
Analysts at Bell Potter noted last month that Mesoblasts balance sheet could come under pressure in the 2022 financial year if there were any hiccups with agreements and payments from partners…
-
General16 hours agoSally Fitzgibbons and Julian Wilson fall short in Gold Coast Pro final
-
Noosa News20 hours agoState launches horse, greyhound racing review
-
General18 hours agoProtesters across country demand end to violence against women during What Were You Wearing? rallies
-
Noosa News23 hours agoQueensland Police to review pursuit policy amid spate of car thefts